CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		110 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
OPERATING EXPENSES
General and administrative	$ 245	$ 480	$ 956	$ 1,297	$ 32,442
Research and development	958	667	2,619	1,626	105,053
Purchased in-process research and development	0	0	0	0	34,311
Other	0	0	0	0	(375)
Total operating expenses	1,203	1,147	3,575	2,923	171,431
Interest and other income, net	(1)	(5)	(155)	(93)	(14,008)
Loss from continuing operations before taxes	1,202	1,142	3,420	2,830	157,423
Income tax benefit	0	0	(21)	0	(1,376)
Loss from continuing operations	1,202	1,142	3,399	2,830	156,047
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	0	0	(2,202)
NET LOSS	1,202	1,142	3,399	2,830	153,845
Less: Net Loss attributable to the noncontrolling interest	0	(191)	(193)	(191)	(667)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 1,202	$ 951	$ 3,206	$ 2,639	$ 153,178
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.03	$ 0.02	$ 0.08	$ 0.06
Basic and diluted shares outstanding (in shares)	40,885	40,885	40,885	40,879